Neovacs S.A. (FRA:0LW1)

Market Cap	15.29K -66.2%
Revenue (ttm)	401.01K -21.8%
Net Income	-4.90M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46
Open	0.0020
Previous Close	0.0040
Day's Range	0.0020 - 0.0020
52-Week Range	0.0020 - 700.0000
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 4, 2026

About Neovacs

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IFNα Kinoid, an anti-interferon alpha vaccine which completed Phase I / IIa and IIb clinical trial for the treatment of lupus erythematosus; and Phase II...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 16
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0LW1

Financial Performance

In 2025, Neovacs's revenue was 401,006, a decrease of -7.59% compared to the previous year's 433,937. Losses were -4.90 million, -85.12% less than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error